



Long-Term Functional Improvement With Zeleciment Basivarsen in the Phase 1/2 ACHIEVE Trial

Karlien Mul, MD, PhD¹, Guillaume Bassez², Jordi Diaz-Manera³, James Lilleker⁴, Marika Pane⁵, Richard Roxburgh⁶, Benedikt Schoaser⁷, Christopher Turner⁸, Allison Kreuzer⁹, Alexandra Lovett⁹, Soma Ray⁹, Huaihou Chen⁹, Shauna Andersson⁹, Douglas Kerr⁹, Valeria Sansone¹⁰

¹Radboud University Medical Center, Nijmegen, the Netherlands; ²Institut de Myologie, Paris, France; ³John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle-Upon-Tyne, UK; ⁴Muscle Disease Unit, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; ⁵Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; ⁶Neurogenetics Clinic Centre for Brain Research, University of Auckland, Auckland, NZ; ⁷Friedrich-Baur-Institute, Dep. of Neurology LMU Clinics, Ludwig-Maximilians University, Munich, Germany; ⁸University College London Hospitals, London, UK; ⁹Dyne Therapeutics, Inc., Waltham, MA, USA; ¹⁰Centro Clinico NeMO, University of Milan, Milan, Italy

WMS2026
HIROSHIMA

**The 31st Annual Congress of
the World Muscle Society**

29 September - 3 October 2026, Hiroshima, Japan

To view an electronic version of this presentation and the related appendix, scan the QR codes below:

Presentation



Appendix





Improvement in Strength Is Sustained at 12 Months, Including Hand Grip, as Measured by QMT (%p)

Quantitative Muscle Testing (QMT) Hand Grip Strength

Pooled Dose Group (N=26)

6.8 mg/kg Cohort




Improvement


Improvement in Motor Function Is Sustained at 12 Months, as Measured by 10MWR Timed Function Test

10-Meter Walk/Run Test

Pooled Dose Group (N=26)



6.8 mg/kg Cohort




Improvement


Improvement Is Observed Across CNS-Related MDHI Subscales Through 12 Months

Communication


Pooled Dose Group (N=26)



Fatigue



Pain






Patients, N

26

26

25

6.8 mg/kg Cohort



Patients, N

Placebo

13

13

6

Improvement

Improvement Is Observed Across CNS-Related MDHI Subscales Through 12 Months

